Shares of Ampio Pharmaceuticals (AMPE-23.3%) sink after an article asserts Ampio's drug Zertane will not be approved by regulators. Ampio has been testing Zertane for the treatment of premature ejaculation, and the drug is currently in Phase III clinical trials. Quoting an (anonymous) biotech fund manager: "Zertane... is laughable and has zero chance of approval."